Preferred Label : Autologous Tumor Cell Proteoliposome Chronic Lymphocytic Leukemia Vaccine;
NCIt definition : An autologous chronic lymphocytic leukemia cancer vaccine consisting of patient-specific
membrane proteins directly extracted from patient autologous tumor cells and incorporated
into liposomes along with Interleukin 2 (IL-2) to produce membrane-patched proteoliposomes,
with potential immunostimulating and antineoplastic activities. After subcutaneous
injection of the autologous tumor cell proteoliposomes chronic lymphocytic leukemia
vaccine, liposomes deliver the encapsulated tumor antigens into the cytosol of antigen
presenting cells (APCs). Subsequently, the APCs process the antigens and present antigen-derived
peptides to the immune system. This may enhance recognition of tumors by the immune
system, and activate both cytotoxic CD8 T cells and CD4 helper T cells against tumor
cells. IL-2 is incorporated into the vaccine to leverage its ability to expand activated
T cells.;
Drug name : Oncoquest-L Vaccine;
Molecule name : Oncoquest-CLL Vaccine;
NCI Metathesaurus CUI : CL454406;
Origin ID : C112206;
UMLS CUI : C3827093;
Semantic type(s)
- concept_is_in_subset
